WHO ICTRP trial
CD19 CAR T–cell therapy for relapse or refractory B-cell Lymphoma and acute B…
ChiCTR-ONN-16009862 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-ONN-16009862 |
|---|---|
| Public title | CD19 CAR T–cell therapy for relapse or refractory B-cell Lymphoma and acute B lymphocytic leukemia |
| Scientific title | CD19 CAR T–cell therapy for relapse or refractory B-cell Lymphoma and acute B lymphocytic leukemia |
| Primary sponsor | Tianjin First Central Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Phase | New Treatment Measure Clinical Study |
| Countries | China |
| Conditions | Relapse or refractory B-cell Lymphoma and acute B lymphocytic leukemia |
| Interventions | The group with autologous stem cell transplantation:autologous stem cell transplantation;Chemotherapy pretreatment group:Chemotherapy |
| Registration date | Nov 14, 2016 |
| Target size | The group with autologous stem cell transplantation:20;Chemotherapy pretreatment… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: